New Oral Gonorrhea Treatments Are Here, But Testing Still Comes First

Published: December 2025 | Last updated: May 2026

A new oral pill for gonorrhea is one of the biggest shifts in sexual-health care in years. On December 12, 2025, the U.S. FDA approved zoliflodacin, sold under the brand name Nuzolvence, a first-in-class oral antibiotic for gonorrhea (GARDP approval announcement). It is the first new class of antibiotic for this infection in nearly two decades, with a related oral candidate, gepotidacin, moving through the regulatory pipeline behind it. For anyone who has ever sat in a clinic waiting for the ceftriaxone shot, that sounds like progress, and it is. What has not changed is the step that comes before any prescription: an accurate diagnosis. Antibiotics, including the newer ones, only help when they are aimed at a confirmed infection. This guide covers what the new oral therapies change, what has stayed the same, and how at-home rapid testing fits if you think you have been exposed.

We publish at stdrapidtestkits.com, which sells at-home STI rapid test kits. We recommend tests based on what fits your situation, not commercial benefit, and when the right next step is a clinic NAAT or a clinician-collected throat swab, we say so plainly.

From FDA approval to your decision: what actually changed

For years, the standard treatment for uncomplicated gonorrhea in the United States has been a single intramuscular injection of ceftriaxone, 500 mg for most adults and 1 gram for people weighing 150 kg or more. The CDC STI Treatment Guidelines have backed that approach partly because gonorrhea, caused by the bacterium Neisseria gonorrhoeae, has out-evolved nearly every oral antibiotic class tried against it. Penicillin worked in the 1940s. Tetracyclines and fluoroquinolones each had their run. Ciprofloxacin was dropped as a recommended treatment in 2007 after resistance climbed sharply in surveillance samples, and dual therapy with azithromycin was removed from CDC first-line guidance in 2020 over rising resistance.

The December 2025 approval of zoliflodacin (Nuzolvence) is the first genuinely new mechanism for treating gonorrhea in nearly twenty years. In its multinational Phase 3 trial, run by the Global Antibiotic Research and Development Partnership (GARDP), a single oral dose cured urogenital infection at rates comparable to the long-standing standard of a ceftriaxone injection. That makes it the first realistic oral option for most uncomplicated urogenital cases. Gepotidacin, an oral candidate from a different new class, has shown similar trial results and is moving through review behind it.

That sounds like a clean win, and the reality is more measured. Zoliflodacin is prescription-only and tied to clinical protocols designed to slow resistance. A provider will not write the prescription on the strength of "I think I might have gonorrhea." They want a confirmed diagnosis, ideally from a NAAT (nucleic acid amplification test), before treating. The approval is also narrow: uncomplicated urogenital infection in adults and adolescents. It does not cover pharyngeal (throat), rectal, or complicated infections, and the manufacturer has signaled a broad commercial launch in the second half of 2026, so availability will vary by region for a while. Ceftriaxone remains the CDC first-line treatment today.

How the new oral drugs differ from older ones

Gepotidacin belongs to a newly developed class, the triazaacenaphthylenes, that hits two essential bacterial enzymes at once: topoisomerase IV and DNA gyrase, at separate sites. Attacking two targets raises the bar for resistance, because the bacterium would need two simultaneous mutations to escape rather than one. The Phase 3 EAGLE-1 trial, which enrolled in 2021 and 2022, tested gepotidacin against a single-dose ceftriaxone injection for urogenital gonorrhea and reported non-inferior cure rates.

Zoliflodacin is a spiropyrimidinetrione, a different class again. It targets type II topoisomerase at a region distinct from where older fluoroquinolones bind, which matters because strains that resist ciprofloxacin, levofloxacin, or other fluoroquinolones can still be vulnerable to zoliflodacin. Laboratory testing has also shown activity against some ceftriaxone-resistant strains, and the trials studied a single oral dose with cure rates comparable to the standard of care at the time.

Both drugs were studied mainly for uncomplicated urogenital infection, meaning penile or vaginal sites. Both have thinner data on extragenital infection (throat and rectum), which the CDC notes is generally harder to clear. That gap matters in practice. Pharyngeal gonorrhea is common in people who have had oral exposure, and a provider may still recommend the ceftriaxone injection for those cases until more extragenital outcome data accumulates. People with a cephalosporin allergy receive gentamicin plus azithromycin as the CDC's recommended alternative.

Why testing comes first, even with a pill on the table

Here is a scenario clinics see constantly. Someone reads "new gonorrhea pill" in a headline, has had a recent risky encounter with maybe a mild symptom or maybe none, and wonders whether they can skip the test and just ask for the prescription. The honest answer is no, and the reason is worth understanding, because it explains why providers are being careful with these drugs.

The WHO estimated 82.4 million new gonorrhea infections worldwide among adults aged 15 to 49 in 2020, and a large share were silent. The CDC reports that most women with gonorrhea have no symptoms, and many infections in men are also quiet, especially in the throat or rectum, where infection often produces no signs at all (NHS gonorrhoea guidance). When symptoms do appear, they overlap with yeast infections, urinary tract infections, ordinary irritation from rough sex or a new lubricant, or strep throat. There is no reliable way to tell gonorrhea apart from those conditions on symptoms alone.

Treating without testing is also a stewardship problem. An antibiotic aimed at the wrong target pushes the bacterium toward resistance, and gonorrhea has already out-evolved every previous class deployed against it, which is one reason the CDC tracks resistance trends so closely. The new drugs are useful precisely because they work against resistant strains, and misusing them shortens their useful life, which harms not just you after a future exposure but everyone sharing the same antibiotic-resistance pressure.

Window period: how long after exposure should you test

The window period is the gap between exposure and the point when an infection becomes reliably detectable. For gonorrhea, the CDC and most diagnostic guidance put that at roughly 7 to 14 days, though detection can begin a little earlier. A test taken on day 2 has a real chance of a false negative even in someone who is infected, simply because the bacterial load has not built up enough to register.

If your anxiety is sharp and you want an early read, you can test in the first few days, but treat that result as preliminary and plan a confirmatory test at day 7 to 14. If symptoms develop in the meantime, an early negative does not rule out infection. If you stay symptom-free after a higher-risk exposure, the day-14 test is the one to trust. You can do this with an at-home gonorrhea test or a clinic NAAT; the timing is the same either way.

That timing applies to both lab NAATs and at-home rapid lateral-flow swabs, because the rate-limiting step is biology rather than test technology. The bacterium needs time to multiply to a detectable level. A lab NAAT can pick up lower bacterial loads than a rapid antigen test, which is one reason it stays the gold standard for confirmation. A pattern we hear about often: someone tests on day 4 after a hookup that felt off, sees nothing, and feels reassured, then a burning sensation at day 10 prompts a retest that comes back positive. The first test was not faulty. It was simply too early.

When you have no symptoms, which is most people

Most gonorrhea infections cause no symptoms at all. Studies of extragenital screening in men who have sex with men have found high silent-carriage rates in the throat and rectum, often above two-thirds of detected cases. The CDC's screening guidance reflects this: routine annual screening for sexually active women under 25, women 25 and older with risk factors, men who have sex with men (with extragenital screening every 3 to 6 months for higher-risk patterns), and pregnant people.

In practice, that means a person can be infected, infectious, and feel completely fine, passing it forward unless they test on a schedule. The cadence depends on risk profile, but the logic holds: symptoms are not a reliable signal, so scheduled screening catches infections that would otherwise stay hidden until they spread or cause complications.

Most women with gonorrhea do not have any symptoms. Untreated, gonorrhea can cause serious and permanent health problems.

Rapid gonorrhea swab, results in about 15 minutes

Gonorrhea At-Home Rapid Self-Test Kit

$59.00

Self-collected genital swab, a lateral-flow rapid test for Neisseria gonorrhoeae antigen. Most reliable from day 7 to 14 after exposure. Confirm any positive with a lab NAAT through your provider before starting treatment.

Test for Gonorrhea

At-home, mail-in lab, or clinic: which route fits

There are three realistic ways to get a gonorrhea result, and they suit different situations. For routine screening when you have no symptoms and you want privacy and speed, an at-home rapid lateral-flow swab gives you an answer in about 15 minutes with no appointment, no clinic copay, and no insurance paperwork that a policyholder might later see on an explanation of benefits. A mail-in lab service lets you collect a sample at home and ship it to a certified lab that runs the same NAAT technology a clinic uses, with results in a few days. A clinic visit is the right call when you have symptoms, when you need a throat or rectal swab, or when you want same-visit treatment. None of these is wrong; the best one depends on what you need that day.

Be clear-eyed about the trade-off. The at-home rapid test is a screening tool. It is lab-comparable for urogenital screening when used correctly after the window period, and a reactive result should always be confirmed by a clinician with a lab NAAT before treatment. It is not a substitute for clinic care when symptoms or throat and rectal exposure are in play.

If your at-home rapid test is positive: what to do next

A test line on a rapid lateral-flow cassette is meaningful even when it is faint, and most kits count any visible test line as positive. Your next move is to contact a clinician, in person or by telehealth, to discuss confirmatory testing and a treatment plan.

Three things usually happen in that conversation. First, the clinician orders a confirmatory NAAT, the lab gold standard, on a swab or urine sample. Second, they take a sexual history to map possible exposure sites: urogenital, throat, rectum. Third, they choose treatment based on where the infection is. Urogenital infection is the best fit for the newer oral drugs, while a pharyngeal or rectal infection may still get the ceftriaxone injection, especially while extragenital data on the new drugs is still accumulating.

Telehealth services in many states can prescribe and ship treatment without an in-person visit, depending on the result and local rules. A provider may also treat for chlamydia at the same time (commonly oral doxycycline), because co-infection is common and joint coverage is often standard. After treatment, avoid sexual contact for at least 7 days, and ideally until any partners from the previous 60 days have also been tested and treated.

Telling partners, and how to start the conversation

Notifying past partners is how you stop continued transmission, and it is often the hardest part of a positive result. The framing that tends to land is collaborative rather than accusatory: you are suggesting you both test, not assigning blame. Something plain works well, along the lines of, "I have been reading about gonorrhea, there is a new oral treatment that just got approved, and I would feel better if we both tested so we have real data instead of guessing." If a partner reacts badly to a basic testing request, that says more about the relationship than about the test. You never need anyone's permission to test yourself. Beyond a direct conversation, two practical paths are worth knowing about.

Resistance and why diagnostic stewardship matters

The reason you cannot grab any antibiotic and assume gonorrhea will clear is that N. gonorrhoeae has steadily defeated every drug class used against it. Sulfa drugs in the 1930s, penicillin through the 1940s and 50s, tetracyclines, then fluoroquinolones in the 1990s and 2000s. By the 2010s, even cephalosporin susceptibility was fraying at the edges in some countries. The CDC lists drug-resistant gonorrhea as a high-priority pathogen for new antibiotic development, and its antibiotic-resistant gonorrhea page tracks U.S. trends in detail.

Diagnostic stewardship, the habit of confirming an infection before treating it, is the main lever public-health authorities are using to extend the useful life of these new drugs. If someone takes zoliflodacin for what turns out to be bacterial vaginosis, the local gonorrhea population sees a sub-therapeutic dose of antibiotic for no reason, and resistant subpopulations get an opening. Multiply that across everyone who might self-medicate, and a drug class that took years to develop loses its lifespan quickly. Providers are therefore tightening prescribing rules even as more treatment options arrive.

Retesting after treatment: timing and reasons

The CDC's STI Treatment Guidelines recommend retesting about three months after gonorrhea treatment, even when you and your provider are confident the antibiotic worked. The reason is reinfection rather than treatment failure. Statistically, reinfection is a far bigger risk than failed clearance, which is rare with current first-line therapy. Many people resume sex before a partner has been treated, or meet a new partner, and the three-month retest catches those cases before they cause downstream harm.

Pelvic inflammatory disease (PID) is the complication people ask about most, and it deserves a real answer. Untreated gonorrhea can climb from the cervix into the upper reproductive tract within days to weeks, inflaming and scarring fallopian-tube tissue. The CDC describes PID as a common complication of untreated chlamydia and gonorrhea, and MedlinePlus notes that untreated gonorrhea can lead to PID and lasting problems with pregnancy and fertility (MedlinePlus on gonorrhea). Each episode adds to the long-term risk of ectopic pregnancy and tubal-factor infertility, which is why early detection and clearance matter well beyond the immediate infection.

For pharyngeal gonorrhea, the CDC recommends a test of cure 7 to 14 days after treatment, because the throat clears less reliably than the genital tract. If your infection was in the throat and your provider has not mentioned a test of cure, ask. The same test of cure applies in pregnancy or when the treatment regimen was not the recommended one. Beyond the three-month mark, retesting cadence follows your activity pattern: annual screening is the floor for sexually active adults under 25, and every 3 to 6 months suits people with multiple partners or other higher-risk patterns.

What at-home rapid testing does, and what it does not

It helps to be precise about what an at-home gonorrhea rapid test is, because the technology category shapes how you read the result.

What it is. A lateral-flow immunoassay using a self-collected genital swab. The kit detects Neisseria gonorrhoeae antigen and shows a visible test line when antigen is present, in roughly 15 minutes. It uses the same swab sample type as a lab NAAT, but the lab assay is a different and more sensitive technology.

What it is not. It is not a NAAT or a PCR test. The lab NAAT stays the diagnostic gold standard, especially for low bacterial loads, silent carriage, and suspected resistant strains. Read a rapid lateral-flow result as a fast screen that can put you and a clinician on the right path quickly, and confirm any positive with a lab NAAT before treatment.

What it cannot test. A genital swab does not detect throat or rectal gonorrhea. Pharyngeal infection needs a clinician-collected throat swab and lab NAAT, and rectal infection needs a clinician- or self-collected rectal swab and lab NAAT. We do not sell either of those at-home kits. If your concern is a sore throat after oral exposure, the right next step is a clinic visit, not a genital swab, so you do not walk away with false reassurance from the wrong test.

If you want to screen more broadly alongside gonorrhea (chlamydia, syphilis, HIV, hepatitis B, and hepatitis C), the 6-in-1 panel below combines those checks into one kit, using the same self-swab and fingerstick blood-drop approach as the single-infection tests.

Bottom line

The new oral pills change the experience of gonorrhea treatment. For most uncomplicated urogenital cases, the injection is no longer the only path. What they do not change is the diagnostic step that comes first: test, confirm, then treat, in that order. If you are worried after an exposure, the fastest route to certainty is usually a rapid swab at day 7 to 14, sooner if symptoms are intense, with the understanding that an early negative is not conclusive. Confirm any positive with a clinic NAAT, and let your clinician pick the right drug for your case, which for now still means ceftriaxone in many situations and the new oral options for the cases that fit them.

Gonorrhea is bacterial, in the same way strep throat is bacterial, and it has no bearing on your character. A test is not a confession. Many people delay testing out of embarrassment, but the infection is a treatable medical condition, and a result is simply the information you need to act on.

1. Global Antibiotic Research and Development Partnership. U.S. FDA approval of Nuzolvence (zoliflodacin), December 12, 2025. Source for the FDA approval date, brand name, and first-in-class oral antibiotic framing.
2. U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines: Gonococcal Infections Among Adolescents and Adults. Source for ceftriaxone 500 mg first-line dosing, alternative regimens, retesting cadence, expedited partner therapy guidance, and the pharyngeal test-of-cure recommendation.
3. U.S. Centers for Disease Control and Prevention. About Gonorrhea. Source for asymptomatic-infection rates by anatomic site and an overview of complications.
4. U.S. Centers for Disease Control and Prevention. Antibiotic-Resistant Gonorrhea Information for Healthcare Providers. Source for resistance trends, the historical antibiotic-class timeline, and the 2007 ciprofloxacin discontinuation.
5. World Health Organization. Gonorrhoea (Neisseria gonorrhoeae infection) fact sheet. Source for the 2020 global incidence estimate of 82.4 million new infections among adults aged 15 to 49.
6. U.S. Centers for Disease Control and Prevention. About Pelvic Inflammatory Disease (PID). Source for the description of PID as a common complication of untreated chlamydia and gonorrhea.
7. National Health Service (UK). Gonorrhoea. Source for the point that not everyone with gonorrhoea has symptoms and that infection can affect the genitals, rectum, and throat.
8. MedlinePlus (U.S. National Library of Medicine, NIH). Gonorrhea. Source for the points that gonorrhea does not always cause symptoms and that untreated infection can lead to pelvic inflammatory disease and infertility.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.